SSA
TPST icon

Schonfeld Strategic Advisors’s Tempest Therapeutics TPST Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-792
Closed -$45.3K – 2413
2023
Q4 		$45.3K Buy
+792
New +$37.5K ﹤0.01% 1673
2021
Q1 		– Sell
-106
Closed -$44K – 2129
2020
Q4 		$44K Sell
106
-56
-35% -$19.4K ﹤0.01% 1502
2020
Q3 		$52K Buy
+162
New +$54.9K ﹤0.01% 1305
2017
Q1 		– Sell
-34
Closed -$153K – 736
2016
Q4 		$153K Buy
34
+31
+1,033% +$386K 0.02% 514
2016
Q3 		$72K Hold
3
– – 0.01% 397
2016
Q2 		$52K Hold
3
– – 0.01% 415
2016
Q1 		$95K Buy
+3
New +$63.4K 0.04% 287

Other funds holding TPST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schonfeld Strategic Advisors's TPST Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Tempest Therapeutics (TPST) in Q1 2024, closing a stake of 792 shares — an estimated $45.3K sold.

Schonfeld Strategic Advisors first reported a position in TPST in Q1 2016 and held it in 7 quarters. The position peaked at $153K in Q4 2016. 28 funds tracked by Wall St. Rank hold TPST as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining Tempest Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 792 Tempest Therapeutics shares in Q1 2024, an estimated $45.3K.
  • Schonfeld Strategic Advisors first reported a position in Tempest Therapeutics in Q1 2016 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Tempest Therapeutics position peaked at $153K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.